Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination drug consisting of metformin and ursodeoxycholic acid (UDCA). Metformin is an antidiabetic medication that improves insulin sensitivity and reduces hepatic glucose production, while UDCA is a hydrophilic bile acid with protective effects on the liver. This combination is being studied for treating non-alcoholic steatohepatitis (NASH) and potentially beneficial for patients with type 2 diabetes mellitus (T2DM) due to its complementary effects on insulin resistance, oxidative stress, and liver protection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metformin + ursodeoxycholic acid.